IP Library Granted Patent US 9,389,336
Granted Patent B2
US 9,389,336 · App. 13/957,497 · Granted Jul 12, 2016

Hydrogel monomer mix containing added water

Inventors: Ritu Shrestha (Rochester, NY); Alok K. Awasthi (Pittsford, NY); Lynn F. Atwater (Ontario, NY); Jay Friedrich Kunzler (Canandaigua, NY); Richard Fanqing Meng (Rochester, NY)
Assignee: Bausch & Lomb Incorporated
G02B1/043A45C11/046
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,389,336
App. No.
13/957,497
Granted
Jul 12, 2016
Kind
B2
Abstract

Provided herein is a polymerized product formed of a polymerized monomer mixture comprising intentionally added water and at least one hydrophilic monomer wherein the monomer mix does not contain any silicon containing materials. The polymerized monomer mixture of the invention herein is useful in many biomaterial applications. Especially preferred is the use of the biomaterial as a hydrogel contact lens.

Claims (14)

1. A hydrogel contact lens formed of a thermally polymerized monomer mixture, the monomer mixture comprising intentionally added water, a hydrophilic monomer, a strengthening monomer, a crosslinker, a thermal initiator and a UV blocker; wherein the monomer mixture does not contain any silicon containing materials and wherein the polymerized monomer mixture is a hydrogel that is optically clear and useful as a hydrogel contact lens in a human eye, and wherein the monomer mixture includes N-vinylpyrrolidone (NVP), 2-hydroxyethyl methacrylate (HEMA), 4-(tertbutyl)-2-hydroxylcyclohexyl methacrylate (TBE) and poloxamer dimethacrylate.

2. The hydrogel contact lens of claim 1 wherein the monomer mixture prior to polymerization comprises 10 to 33 percent by weight of intentionally added water.

3. The hydrogel contact lens of claim 1 wherein the monomer mixture prior to polymerization comprises 10 to 20 percent by weight of intentionally added water.

4. The hydrogel contact lens of claim 1 wherein the monomer mixture prior to polymerization comprises 10 to 15 percent by weight of intentionally added water.

5. The hydrogel contact lens of claim 1 wherein the monomer mixture prior to polymerization comprises 15 to 33 percent by weight of intentionally added water.

6. The hydrogel contact lens of claim 1 wherein the monomer mixture prior to polymerization comprises 15 to 20 percent by weight of intentionally added water.

7. The hydrogel contact lens of claim 1 wherein the monomer mixture prior to polymerization comprises 20 to 33 percent by weight of intentionally added water.

8. The hydrogel contact lens of claim 1 , wherein the monomer mixture further comprises a tint and a crosslinker and hydrating agent.

9. A hydrogel contact lens formed of a polymerized monomer mixture, wherein the monomer mixture comprises: intentionally added water; N-vinylpyrrolidone (NVP); 2-hydroxyethyl methacrylate (HEMA); ethyleneglycoldimethacrylate (EGDMA); allyl methacrylate (AMA); 4-(tertbutyl)-2hydroxylcyclohexyl methacrylate (TBE); poloxamer dimethacrylate; azobisisobutyronitrile (AIBN) as a thermal initiator; SA monomer as a UV blocker; and IMVT as a tint, and wherein the monomer mixture does not contain any silicon containing materials.

10. The hydrogel contact lens of claim 9 , wherein the monomer mixture further comprises a diluent.

11. The hydrogel contact lens of claim 10 , wherein the diluent is propylene glycol.

12. The hydrogel contact lens of claim 9 contained in a package, wherein the package comprises a flange with a well formed therein and a flexible cover sheet extending over the flange and sealed about the perimeter of the well, wherein the hydrogel contact lens is immersed in an aqueous solution and held in the well.

13. The hydrogel contact lens of claim 9 , wherein the monomer mixture prior to polymerization comprises 10 to 33 percent by weight of intentionally added water.

14. The hydrogel contact lens of claim 9 , wherein the monomer mixture prior to polymerization comprises 10 to 15 percent by weight of intentionally added water.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 048715/0406) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061775/0290 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2013
From: SHRESTHA, RITU; AWASTHI, ALOK K.; ATWATER, LYNN F.; KUNZLER, JAY FRIEDRICH; MENG, RICHARD FANQING
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 030931/0663 →
Continuity (1)
Related Publication 20140034519A1 · Feb 6, 2014